|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- July 1, 2008
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Acusphere Inc., of Watertown, Mass., said its new drug application for Imagify (perflubutaine polymer microspheres for injectable suspension) was accepted for review by the FDA. Imagify is an ultrasound imaging agent for the detection of coronary artery disease. With a standard review, the agency's target action date is Feb. 28, 2009.
Adventrx Pharmaceuticals Inc., of San Diego, received $600,000 from Research Triangle Park, N.C.-based Theragenex LLC resulting from a dispute regarding Theragenex's alleged breach of contract concerning the license of Adventrx's antiviral, ANX-211. The two companies jointly dismissed all claims.
Agilent Technologies Inc., ...